0.16% -0.001

Chromocell Therapeutics Corp (CHRO)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Chromocell Therapeutics Corp Stock (CHRO) Company Profile

Chromocell Therapeutics Corp

Healthcare (1196)

Biotechnology (683)

(917) 644-6313

685 US HIGHWAY ONE, NORTH BRUNSWICK

최신 SEC 제출 서류

CHRO's Discussions on Twitter

CHRO을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CHRO	0.63	3.75M	0	0	0	0.00
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Chromocell Therapeutics Corp 주식(CHRO)의 최신 뉴스

Chromocell Therapeutics Corp (CHRO) 재무 분석

Chromocell Therapeutics Corp (CHRO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Chromocell Therapeutics Corp (CHRO)

Chromocell Therapeutics Corp Stock (CHRO) Company Profile

CHRO을(를) 다른 주식과 비교

Chromocell Therapeutics Corp 주식(CHRO)의 최신 뉴스

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times

Chromocell Therapeutics Corporation Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - Marketscreener.com

Chromocell to Present at Upcoming Fall Investor Conferences - The Manila Times

Chromocell announces amendment to stock repurchase plan - MSN

Chromocell Therapeutics amends stock repurchase plan - TradingPedia

Chromocell boosts stock buyback plan to $750,000 - Investing.com India

Chromocell Announces Amendment to Stock Repurchase Plan - The Manila Times

Chromocell boosts stock buyback plan to $750,000 By Investing.com - Investing.com South Africa

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Upward Trajectory: Chromocell Therapeutics Corp. (CHRO) Posts a Slidee, Closing at 0.84 - The Dwinnex

CHRO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Chubb (CB) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance

Stocks of Chemours Company (CC) are poised to climb above their peers - SETE News

Chubb Limited [CB] stock was sold by GREENBERG EVAN G at the price of US$8.78 million - Knox Daily

Recent 4.1% pullback isn't enough to hurt long-term Calumet (NASDAQ:CLMT) shareholders, they're still up 373% over 5 years - Yahoo Finance

Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $18.00 - Defense World

Market Update: Calumet Inc. (CLMT) Sees Negative Movement, Closing at 18.00 - The Dwinnex

C.H. Robinson Worldwide Sees Unusually High Options Volume (NASDAQ:CHRW) - MarketBeat

CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India

CG Oncology initiated with an Outperform at RBC Capital - TipRanks

Comparing BioLargo (NASDAQ:BLGO) and Chemours (NYSE:CC) - Defense World

Chubb Stock Trading Near 52-Week High: What Should Investors Know? - Yahoo Finance

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Morningstar

Choreo LLC Purchases New Stake in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) - Defense World

Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard

CorMedix stock soars to 52-week high, hits $7.29 By Investing.com - Investing.com Australia

Investor’s Delight: Calumet Inc. (CLMT) Closes Weak at 18.24, Down -0.27 - The Dwinnex

Analyzing Calumet Inc. (CLMT) After Recent Trading Activity - Knox Daily

Another Delaware Publicly Traded Company Proposes A Nevada Move - The National Law Review

Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St

Chubb (CB) Rises Higher Than Market: Key Facts - Yahoo Finance

Chromocell therapeutics CEO buys $5,044 in company stock By Investing.com - Investing.com Canada

Chromocell therapeutics director buys $9.8k in stock - Investing.com

Chromocell therapeutics CEO buys $5,044 in company stock - Investing.com India

Chubb Ltd. stock rises Monday, outperforms market - MarketWatch

Life Sciences Virtual Investor Forum Agenda Announced for September 19th - GlobeNewswire

Chromocell to Participate in Life Sciences Investor Forum September 19th - GlobeNewswire

Calumet Specialty Products Partners (NASDAQ:CLMT) Shares Gap Down to $16.58 - Defense World

Chromocell Therapeutics CEO buys shares worth over $10,000 By Investing.com - Investing.com Australia

Market Recap Check: Calumet Inc. (CLMT)’s Positive Finish at 16.58, Up/Down 10.31 - The Dwinnex

Chromocell Therapeutics CEO buys shares worth over $10,000 - Investing.com

IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online

Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024 - MSN

Chromocell announces $250,000 stock repurchase plan By Investing.com - Investing.com Australia

Chromocell Therapeutics announces stock repurchase plan up to $250,000 - TipRanks

Chromocell Therapeutics Co.’s Lock-Up Period Will End on August 14th (NYSE:CHRO) - Defense World

Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC

Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga

Chromocell Therapeutics Corp (CHRO) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CHRO과 유사한 종목